SGS-742 has been used in trials studying the treatment of Seizures and Metabolic Disease.
- Mechanism
- Curator reviewed
SGS742 blocks the late inhibitory postsynaptic potential and the paired-pulse inhibition of population spikes recorded from CA1 pyramidal neurons of the hippocampus of rats in vitro and in vivo. SGS742 significantly enhances the release of glutamate, aspartate, glycine and somatostatin in vivo. Chronic administration of SGS742 causes an up-regulation of GABA(B) receptors in the frontal cortex of rats. Single doses cause a significant enhancement of the mRNA and protein levels of NGF and BDNF in the cortex and hippocampus of rats.
- Primary indication
- Investigated for use/treatment in alzheimer's disease, attention deficit/hyperactivity disorder (ADHD), memory loss, and schizophrenia and schizoaffective disorders.Curator reviewed
- Formula / weight
- C7H18NO2P · 179.2 g/mol (avg)
- Also known as
- (3-Aminopropyl)(n-butyl)phosphinic acid · 3-Aminopropyl-Butyl Phosphinic Acid
- Code names
- CGP-36742 · LU-AE-58479 · SGS742
Resolves to
ONNMDRQRSGKZCN-UHFFFAOYSA-NSMILESCCCCP(O)(=O)CCCNWhat you can answer from here — as of January 29, 2025
Which drugs share a target with SGS-742, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account